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Background: Polymorphisms spanning genes involved in the production of leukotriene B4 (LTB4) e.g. ALOX5AP and
LTA4H are associated with asthma susceptibility, suggesting a role for LTB4 in disease. The contribution of LTB4
receptor polymorphism is currently unknown. The aim of this study was to characterise the genes for the two
pivotal LTB4 receptors, LTB4R1 and LTB4R2 in lung tissue and determine if polymorphisms spanning these genes are
associated with asthma and disease severity.
Methods: Rapid amplification of cDNA ends (RACE) was used to characterise the LTB4R1 and LTB4R2 gene structure
in lung. The LTB4R1/2 locus on chromosome 14q11.2 was screened for polymorphic variation. Six LTB4R single
nucleotide polymorphisms (SNPs) were genotyped in 370 Caucasian asthma families and 299 Adult Asthma
Individuals (n=1877 total) and were evaluated for association with asthma and severity (BTS) outcome measures
using Family Based Association Test, linear regression and chi square.
Results: LTB4R1 has complex mRNA arrangement including multiple 50-untranslated exons, suggesting additional
levels of regulation. Three potential promoter regions across the LTB4R1/2 locus were identified with some airway
cell specificity. 22 SNPs (MAF>0.01) were validated across the LTB4R locus in the Caucasian population. LTB4R1 and
LTB4R2 SNPs were not associated with asthma susceptibility, FEV1 or severity.
Conclusions: LTB4R1 and LTB4R2 shows splice variation in the 50-untranslated region and multiple promoter
regions. The functional significance of this is yet to be determined. Both receptor genes were shown to be
polymorphic. LTB4R polymorphisms do not appear to be susceptibility markers for the development of asthma in
Caucasian subjects.
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Asthma is a multifactorial respiratory disease with gen-
etic and environmental contributing factors. Leuko-
trienes are lipid mediators known to be involved in
allergic conditions such as asthma and are generated by
a series of enzymes and proteins which form the 5-
lipoxygenase (5-LO) pathway [1]. There are two types of
leukotriene; cysteinyl leukotrienes (CysLTs), which are
potent bronchoconstrictors, and the dihydroxy leuko-
triene, leukotriene B4 (LTB4) a chemoattractant and acti-
vator of leukocytes. CysLTs have long been reported as
important mediators contributing to inflammatory dis-
eases such as asthma [2]. Recent data supports a role for* Correspondence: ian.sayers@nottingham.ac.uk
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reproduction in any medium, provided the orLTB4 in asthma pathophysiology. LTB4 is elevated in the
airways of asthma subjects and its concentration corre-
lates with asthma severity [3,4].
Polymorphisms within genes encoding constituents of
the 5-LO pathway provide excellent candidates for mar-
kers of asthma susceptibility. Polymorphisms in two 5-
LO pathway genes; 5-lipoxygenase activating protein
(ALOX5AP) and leukotriene A4 hydrolase (LTA4H) have
shown an association with LTB4 overproduction from
ionomycin-stimulated neutrophils and with myocardial
infarction (MI) susceptibility [5,6]. 5-lipoxygenase acti-
vating protein (FLAP) is an adapter protein for the rate-
limiting enzyme 5-lipoxygenase and is involved in the
production of all leukotrienes; however LTA4H is specif-
ically involved in LTB4 production. We and others have
recently provided preliminary evidence that SNPstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ity markers and determinants of lung function [7,8].
Polymorphisms spanning ALOX5, LTC4S, CYSLTR1 and
CYSLTR2 have also shown association with asthma-
related traits, reviewed in [9].
Two G protein-coupled receptors (GPCRs) for LTB4
encoded by LTB4R1 and LTB4R2 have been described
and are located together on chromosome 14q11.2
[10,11]. LTB4 via its receptors is important in the re-
cruitment and activation of leukocytes to sites of inflam-
mation [12] and these receptors have been proposed as
potential therapeutic targets in asthma. Increasing our
understanding of the expression, regulation and poten-
tial function of these receptors may provide important
information for the design of therapeutic agents. Cur-
rently, relatively little is known about LTB4R1 and
LTB4R2 gene structure, splice variation and polymorphic
variation and the contribution of polymorphic variation
to asthma and disease severity.
The aims of this study were to 1) investigate the gene
structure of human LTB4R1 and LTB4R2 in cells and tis-
sues relevant to asthma; 2) determine the extent and na-
ture of polymorphic variation across the receptor locus
and 3) determine if LTB4R polymorphisms were asso-
ciated with asthma, lung function and disease severity in
asthma families and adult asthma subjects. Our data
suggest that LTB4R1 and LTB4R2 have complicated gene
structure and are polymorphic and that polymorphisms
spanning the LTB4R locus are not determinants of
asthma susceptibility.
Methods
Cell culture and RNA/cDNA preparation
Human airway smooth muscle (HASM) cells were iso-
lated and cultured as previously described [13]. Primary
human bronchial epithelial cells (HBEC) were obtained
from Lonza (Wokingham, UK) and cultured in bronchial
epithelial growth medium (BEGM, Lonza, UK), using
bronchial epithelial differentiation medium (BEDM,
Lonza, UK) cells were differentiated at air-liquid inter-
face [14,15]. The bronchial epithelial cell line BEAS-2B
and a leukemic monocyte cell line, THP-1, were also cul-
tured as described previously [14,16]. Commercial RNA
for the lung, brain and placenta was obtained from
Ambion (Huntingdon, UK) and peripheral blood mono-
nuclear cells (PBMC), polymorphonuclear cells (PMN)
was obtained from 3H Biomedical (Uppsala, Sweden).
Cells were lysed and RNA extracted (from at least two
different donors) using the RNeasy mini kit (Qiagen,
Crawley, UK), as described by the manufacturer. cDNA
was prepared using the Superscript first strand cDNA
synthesis kit (Invitrogen, Paisley, UK) using random hex-
amers and 0.5-1.0μg total RNA per reaction, as directed
by manufacturer.Rapid amplification of cDNA ends (RACE)
RACE was performed using the GeneRacer kit (Invitro-
gen) and Superscript II as directed [14]. RACE-ready
lung cDNA was synthesised from 1μg total lung RNA
obtained from Ambion (Huntingdon, UK) as described.
Gene-specific primers were designed for 50 and 30 RACE
in the coding region in an overlapping fashion. Plasmid
DNA from RACE PCR clones was prepared using the
DNA Miniprep kit (Qiagen) and sequenced with M13F
and M13R vector primers using Big Dye v3.1 (Applied
Biosystems) and an ABI 310 DNA sequencer. Sequence
data was aligned to the human database using the Basic
Local Alignment Search Tool (BLAST) 2 sequence align-
ment program.
Polymorphism screening
The extended LTB4R1 and LTB4R2 genomic region
identified by RACE (~11.5kb, NCBI build 37:
+14:24776125–24787584) was amplified by multiple
PCR reactions and screened for polymorphisms by direct
sequencing using DNA extracted from whole blood of
35 individuals from the Nottingham Adult Asthma Co-
hort recruited on the basis of physician diagnosed
asthma and no other respiratory illness with <10 pack-
years smoking history. These subjects had severe asthma
as defined by British Thoracic Society (BTS) step ≥ 3.
Single nucleotide polymorphisms (SNPs) were identified
by examining chromatograms and BLAST analysis of se-
quencing traces. Any potential SNP identified was vali-
dated by sequencing on the reverse strand of DNA.
Ethical approval was obtained from the Nottingham
University Hospitals local ethics committee.
Subjects for association analyses
341 Caucasian families (n=1508) with at least two bio-
logical siblings with physician diagnosed asthma were
recruited from the Southampton area. This cohort has
been described in detail previously [17]. Baseline FEV1
(forced expiratory volume in one second) was measured
as best of three values within 5% performed using Vita-
lograph dry-wedge bellows spirometer (Vitalograph Ltd,
Buckingham, UK) and determined 14 days after respira-
tory tract infection or use of bronchodilator or anti-
allergic medication. 46 Caucasian families (n=184) with
at least two biological siblings with physician diagnosed
asthma from the Nottingham area [17] were also
recruited. Baseline lung function tests were performed,
FEV1 defined as the best of three values. The Notting-
ham and Southampton cohorts were combined to gener-
ate a UK family cohort (n=370). A cohort comprising
299 unrelated adult European Caucasian individuals
recruited from Nottingham and Padova was used [18].
Individuals were 16–60 years, had asthma for >1 year
with no other respiratory illness and <10 pack-years
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jects were classified according to British Thoracic Society
Step Guidelines (BTS steps, ranging from step 1 to step
5) based on physician prescribed medication [19]. Ethical
approval was obtained from the Nottingham University
Medical School, the Padova Local Ethics Committees
and the Southampton and South West Hampshire and
the Portsmouth and South East Hampshire Local Re-
search Ethics Committees. Informed consent was pro-
vided by the adult (or parent/guardian for child subjects).
SNP selection and genotyping
LTB4R SNPs were chosen for their ability to tag linkage
disequilibrium (LD) blocks using Tagger software [20] or
for inferred function. Sequencing data from the severe
asthma subjects and available HapMap data (Build 36)
were used to select the six SNPs for analysis. We
acknowledge a limitation of the current study is the use
of this available HapMap build that has now post SNP
selection been superseded by 1000 genomes data. Six
SNPs which captured the information for eight SNPs
were selected. SNPs were also chosen due to potential
functional significance. rs11158635 (LTB4R2, 50UTR)
tagged two SNPs (rs11158634 and rs2748543, both
LTB4R2, 50UTR) and rs3181384 (LTB4R1, 30UTR) previ-
ously showed association with cardioembolic stroke in
another study [21]. rs2224122 (LTB4R2, 50UTR) was pre-
dicted as an intronic enhancer according to FASTSNP
algorithm [22]. SNPs were genotyped by KBiosciences
using KASPar (Hertfordshire, UK). Chi square was
used to test for any deviation of the observed geno-
type frequency from the expected values under Hardy
Weinberg Equilibrium. Allele frequencies between the
UK and Italian subjects were not statistically different
(data not shown).
Association analyses
The family based association test (FBAT) software (ver-
sion 1.5.1) [23] was used for association analyses in the
family cohorts between LTB4R SNPs and phenotypic
scores using the additive model. For analysis in the
Adult Asthma Cohort, SPSS (version 15, SPSS Inc., Chi-
cago, IL) was used to determine the contribution of each
SNP to baseline percent predicted FEV1 using linear re-
gression in the additive model. For dichotomised pheno-
types, unadjusted contingency table analysis using the
allelic model was completed using GraphPad Prism (ver-
sion 5, San Diego, CA). Analyses in the adult asthma co-
hort were not corrected for any potential confounders to
enable comparison of the association analysis between
family-based and adult cohorts. Based on our study with
six SNPs and three outcomes analysed, Bonferroni cor-
rection would suggest a p<0.003 when reporting results
as statistically significant. There was between 0.814 (fora MAF of 0.096) and 0.990 (for a MAF of 0.494) power
to detect an association with a significance level of
p=0.05 and a relative risk of 1.5.
Results
Identification of LTB4R1 and LTB4R2 splice variants and
promoter regions
There was ubiquitous expression of LTB4R1 and LTB4R2
mRNA in the airway and periphery cells, including lung,
HASM, HBEC, PBMC, PMN, BEAS-2B and THP-1
(data not shown). 50 RACE data for LTB4R1 and LTB4R2
was generated for lung tissue (Figure 1). Three LTB4R1
50 variants were identified by 50 RACE in the lung which
suggested a structure of four exons, with exon four (con-
taining the protein coding region) being present in every
variant identified. LTB4R1 50 variant A was the most
prevalent present in 50% of clones analysed (10 clones).
A PCR-based assay validated this variant in lung,
HASM, HBEC, PBMC, PMN, BEAS-2B and THP-1
(Figure 2). LTB4R1 50 variant B was present in 35% of
clones (7 clones). LTB4R1 50 variant C was identified at
lower frequency, 15% of clones (3 clones). LTB4R1
50RACE data suggested the presence of two potential
transcription start sites (TSS), at position −4150 to
−4148 and one in the region −748 to −758 relative to
the LTB4R1 ATG. 30 RACE data from the lung identified
the presence of two variants; LTB4R1 30 variant 1 present
in 55% of clones (11 clones) and LTB4R1 30 variant 2
was present in 45% of clones (9 clones). LTB4R2 showed
a more conserved structure based on RACE data. Only
one 50 structure was identified in all clones analysed (20
clones) which was validated in lung, HBEC, PBMC,
BEAS-2B and THP-1 using PCR (Figure 2). The 30
RACE data also showed a conserved structure, a 310bp
untranslated region in all (n=20) clones analysed
(Figure 1). We conducted an in silico analysis of the re-
gion 1.5kb upstream of the predicted three transcription
start sites (data not shown). Multiple consensus
sequences for Sp-1, AP-1 (activator protein 1), GATA,
cAMP-response element binding protein, STAT (signal
transducer and activator of transcription) and GR
(glucocorticoid receptor) were identified.
LTB4R1 and LTB4R2 sequencing
Direct sequencing in 35 individuals revealed 22 SNPs
validated across the region (Table 1 and Figure 1). Four
were novel SNPs and identified at low frequency (MAF
<0.01) at position −7686, -5918, -5866, -5737 (in the
LTB4R2 50-untranslated region), all positions are relative
to the LTB4R1 ATG. 18 of these SNPs have now been
reported (1000genomes and NCBI Build 37). Of note,
the non-synonymous SNPs identified in Asian popula-
tions in LTB4R1 (rs34645221, Ala79Ser and rs17849864,
Leu346Phe) and LTB4R2 (rs1950504, Asp196Gly) were
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Figure 1 Schematic representation of the human LTB4R2 and LTB4R1 genes on chromosome 14 showing overlapping gene structure
and polymorphic variation. Black boxes represent coding; LTB4R2 (left), LTB4R1 (right) and white boxes, non-coding exon sequence, space in-
between represent intron. Data suggest LTB4R1/LTB4R2 expression can be directed by at least three different promoter regions 50 to the marked
TSS (underlined). Validated polymorphisms in Caucasians are shown; positions relative to the LTB4R1 ATG start codon (+1). SNPs numbered 1–6
correspond to genotyped SNPs in Table 3.
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onymous coding region SNPs were identified, both in
LTB4R1. rs3742511 (Ser18Ser) located in the extracellu-
lar N-terminus and rs1046584 (Gly309Gly) located in
the cytosolic C-terminus.
LTB4R polymorphisms are not associated with asthma,
lung function or disease severity
The clinical characteristics for all study cohorts are
shown in Table 2. The family cohort contains children
with asthma (mean age sibling 1 was 13.3±4.4 years andsibling 2 was 10.3±4.6 years) and the second asthma co-
hort is comprised of asthma adults (mean age 39.2±12.3
years, n=299). Genotyping data for the six SNPs did not
show deviation from the Hardy-Weinberg Equilibrium
(p>0.05). Minor allele frequencies (MAF) were similar
across the different study cohorts. The haplotype struc-
ture of the LTB4R region generated using the genotyping
data in the cohorts is shown in Figure 3. Analysis of LD
across these SNPs indicated some redundancy in the
genotyping with high LD between several LTB4R SNPs
e.g. rs11158635, rs2516564 and rs2224122.
Figure 2 Profiling LTB4R1 and LTB4R2 variants in lung and peripheral cells. PCR was used to screen for the 50RACE variants in various cells
and tissues. A common reverse PCR primer was designed in the LTB4R1 open reading frame sequence and different forward PCR primers were
designed to assay for the four variants. RT- samples did not show any amplification signals (data not shown). HASM: human airway smooth
muscle; HBECu: undifferentiated human bronchial epithelial cells; HBECd: differentiated human bronchial epithelial cells; PBMC: peripheral blood
mononuclear cell; PMN: polymorphonuclear neutrophil; BEAS-2B: human bronchial epithelial cell line; THP-1: human acute monocytic leukemia
cell line.
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ciated with asthma diagnosis, FEV1 or severity (BTS) in
the families (Table 3). In the Adult Asthma Cohort we
completed baseline percent predicted FEV1 analyses
(Table 4), and again did not observe any significant asso-
ciations. We retrospectively evaluated SNPs spanning
ALOX5AP (8 SNPs) and LTA4H (6 SNPs) that encode
for proteins involved in LTB4 production and had previ-
ously been associated with asthma susceptibility [7] with
BTS defined severity (step 1–5). Interestingly, while no
association survived correction for multiple testing,
modest associations in the family cohort were observed
with multiple ALOX5AP SNPs, e.g. SG13S41G (intron 4)
(p=0.005, z=+2.778) and SG13S114A (intron 1)
(p=0.017, z=+2.397). LTA4H SNP also showed modest
association e.g., rs2540482C (50UTR) (p=0.014, z=
−2.468) (Table 5). Our previous study [7] analysed the
effect of these same SNPs in determining asthma sever-
ity, but used an in house generated asthma severity
score, which showed the same SG13S41G SNP with a
p=0.021 and the same direction of effect as the present
study. In the Adult Asthma Cohort dichotomised ana-
lysis of BTS 1 versus BTS ≥4 showed no significant asso-
ciation with any SNP tested (data not shown).
Discussion
Both LTB4R1 and LTB4R2 receptors are potentially
important drug targets for conditions driven byinflammation involving LTB4. LTB4 production and ac-
tivity is thought to be particularly important in severe
asthma where a neutrophilic inflammation is more com-
monly observed [24]. The aims of this study were to
characterise the LTB4R1/2 locus at the molecular level
to identify key regulatory regions (TSS, promoter
regions), splice variation and polymorphic variation in
lung tissue and to investigate the potential contribution
of polymorphic variation to asthma susceptibility and se-
verity. Our data show that LTB4R1 and LTB4R2 mRNA
is ubiquitously expressed in multiple lung and peripheral
cell types and that these genes are complex and have
variation in 50-untranslated regions and predicted pro-
moter regions which may be functional in terms of cell-
specific regulation. We also show that the LTB4R1/2
locus is polymorphic (22 SNPs spanning ~11.5kb,
MAF>0.01), with most variation in the untranslated
regions. This study does not provide evidence supporting
a role for LTB4R SNPs in susceptibility to develop
asthma or severity phenotypes using asthma enriched
families and adult asthma subjects. However, retrospect-
ive analyses of SNPs spanning ALOX5AP and LTA4H
provided some evidence for association with BTS defined
severity although this did not survive correction for mul-
tiple testing. This study represents the first characterisa-
tion of the LTB4R locus with respect to gene structure in
the lung and the first evaluation of LTB4R SNPs for as-
sociation with asthma susceptibility and severity.
Table 2 Clinical characteristics of the study cohorts
Asthma Families Adult Asthma
CohortPedigrees Sibling 1 Sibling 2
Age (years, mean±SD) 26.2±1.6 13.3±4.4 10.3±4.6 39.24±12.31
Gender (%, Female) 50.8 54.6 53.7 65.6
Asthma (%, Doctor diagnosed) 61.6 100 100 100
FEV1 (% Predicted) (mean±SD) ND 95.4±15.6 96.2±14.9 92.37±20.57
Positive skin prick test (%) 62.5 73.9 65.1 64.3
Eczema (%, questionnaire) 41.1 53.5 55.1 31.8
Hay fever (%, questionnaire) 50.2 64.9 47.4 64.5
Log total serum IgE (mean) 2.04 2.33 2.33 2.03
Step on BTS guidelines (%):
• Step 1 19.1 24.9 23.8 13.7
• Step 2 32.5 52.7 55.7 17.7
• Step 3 6.1 11.6 10.2 50.9
• Step ≥4 4.7 9.2 6.7 17.7
n 1578 370 361 299
Table 1 SNPs identified from polymorphism screening in asthmatic subjects.
SNP Alleles
(major/minor)
Location Gene location
(amino acid)
Individuals
sequenced (n)
Minor allele
frequency
rs2332320 T/C −8639 LTB4R2 50UTR 43 C=0.128
rs1053648 C/T −8513 LTB4R2 50UTR 43 T=0.035
rs1053649 A/C −8456 LTB4R2 50UTR 43 C=0.035
rs11158634 C/G −8401 LTB4R2 50UTR 43 G=0.244
rs11158635 G/T −8088 LTB4R2 50UTR 43 T=0.244
Novel 1 C/G −7686 LTB4R2 50UTR 35 G=0.014
rs2144492 C/A −7446 LTB4R2 50UTR 35 A=0.043
rs2180197 G/C −7266 LTB4R2 50UTR 35 C=0.043
rs45512098 C/G −6743 LTB4R2 50UTR 41 G=0.024
rs2516564 C/T −6215 LTB4R2 50UTR 41 T=0.22
rs2748543 C/A −6184 LTB4R2 50UTR 42 A= 0.27
Novel 2 G/A −5918 LTB4R2 50UTR 42 A=0.012
Novel 3 C/G −5866 LTB4R2 50UTR 42 G=0.012
Novel 4 G/C −5737 LTB4R2 50UTR 42 C=0.012
rs2224122 G/C −1444 LTB4R1 50UTR 43 C=0.163
rs374510 G/C −1177 LTB4R1 50UTR 44 C=0.011
rs3742511 T/C +53 LTB4R1 ORF (S/S) 39 C=0.026
rs1046584 C/T +926 LTB4R1 ORF (G/G) 39 T=0.28
rs1046587 G/A +1202 LTB4R1 30UTR 41 A=0.48
rs4981503 G/T +1435 LTB4R1 30UTR 41 T=0.11
rs3181384 C/T +2118 LTB4R1 30UTR 42 T=0.286
rs111415008 A/C +2555 LTB4R1 30UTR 41 C=0.012
The LTB4R locus was sequenced in 35 asthmatic subjects. 22 SNPs were validated, of which four were novel. Those SNPs with rs numbers correspond to those
reported in the 1000genomes project and dbSNP (NCBI build 37).
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Table 3 LTB4R SNP association analysis with asthma, FEV1 and BTS score 1 to 5 in 370 families
SNP no.* SNP Gene Location Alleles MAF Asthma FEV1 BTS (1–5)
Fam Z-score P-value Fam Z-score P-value Fam Z-score P-value
LTB4R2
1 rs2332320 50UTR T/C 0.096 116 −0.173 0.863 121 −0.350 0.726 118 −1.000 0.317
2 rs11158635 50UTR G/T 0.211 202 −0.648 0.517 211 −0.813 0.416 204 +0.386 0.699
3 rs2516564 50UTR C/T 0.212 215 −1.109 0.268 221 −1.288 0.198 218 −0.060 0.952
LTB4R1
4 rs2224122 50UTR C/G 0.214 208 −0.907 0.365 217 −1.193 0.233 212 +0.103 0.918
5 rs1046587 30UTR G/A 0.494 282 −1.204 0.229 287 −1.391 0.164 287 −1.006 0.314
6 rs3181384 30UTR C/T 0.215 207 −0.895 0.371 215 −1.190 0.234 211 +0.157 0.875
The z score indicates the direction of the association (+ means the allele was overtransmitted = risk and – means undertransmitted = protection with respect to
asthma affection; for continuous traits + indicates the allele confers higher trait values and – indicates the allele confers lower trait values). The z score is a
measure of transmission equilibrium i.e. the deviation from the number of times an allele was transmitted to affected offspring and the number of times it should
be transmitted under the null hypothesis of no association, no linkage. Number of families in analysis (≥10 families). *SNP location shown on Figure 1.
Asthma Families                                 Adult Asthma Cohort 
B
A
C
Figure 3 Schematic diagram showing the location and linkage disequilibrium of LTB4R SNPs genotyped. The LD plot shows the LD
displayed as r2 in Haploview software [20]. Numerical values shown correspond to r2. A. represents the physical location of the SNPs genotyped.
Black boxes represent exons and the spaces between introns determined by RACE. B. and C. represents the LD plot in the Asthma Families
(n=370 families) and the Adult Asthma Cohort (n=299 individuals) respectively.
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Table 5 ALOX5AP and LTA4H SNP association analysis
with BTS score 1 to 5 in 370 families
SNP Gene Location Alleles MAF Fam Z-score P-value
ALOX5AP
SG13S25 50UTR G/A 0.109 118 +0.977 0.329
SG13S114 Intron1 T/A 0.323 245 +2.397 0.017
rs3803277 Intron2 C/A 0.445 283 +1.818 0.069
SG13S89 Intron3 G/A 0.042 54 +1.886 0.059
rs4468448 Intron4 C/T 0.242 239 +1.183 0.237
SG13S32 Intron4 C/A 0.474 272 +1.617 0.106
SG13S41 Intron4 A/G 0.067 80 +2.778 0.005
SG13S35 30UTR G/A 0.078 97 +1.057 0.291
LTA4H
rs1978331 Intron11 T/C 0.417 261 −1.865 0.062
rs17677715 Intron6 T/C 0.193 187 −1.974 0.048
rs2540482 50UTR T/C 0.222 209 −2.468 0.014
rs2660845 50UTR A/G 0.261 225 −0.856 0.392
rs2540475 50UTR C/T 0.215 212 −1.103 0.270
The z score indicates the direction of the association (for continuous traits +
indicates the allele confers higher trait values and – indicates the allele confers
lower trait values). The z score is a measure of transmission equilibrium i.e. the
deviation from the number of times an allele was transmitted to affected
offspring and the number of times it should be transmitted under the null
hypothesis of no association, no linkage. Number of families in analysis (≥10
families).
Table 4 Baseline lung function (FEV1) and LTB4R SNPs in
the adult asthma cohort
SNP MAF p-value (R2) Group (n) Value, % (Mean ± SEM)
LTB4R2
*rs2332320 0.10 0.703 0 (210) 92.568 ± 1.424
(50UTR) (0.001) 1 (50) 91.331 ± 2.918
rs11158635 0.19 0.421 0 (168) 93.592 ± 1.599
(50UTR) (0.007) 1 (79) 90.047 ± 2.331
2 (11) 89.882 ± 6.247
rs2516564 0.19 0.422 0 (170) 93.529 ± 1.592
(50UTR) (0.007) 1 (77) 89.871 ± 2.365
2 (10) 90.412 ± 6.564
LTB4R1
rs2224122 0.20 0.599 0 (166) 93.469 ± 1.588
(50UTR) (0.004) 1 (81) 90.802 ± 2.274
2 (12) 90.642 ± 5.907
rs1046587 0.49 0.761 0 (73) 90.804 ± 2.436
(30UTR) (0.002) 1 (118) 92.044 ± 1.916
2 (67) 93.409 ± 2.543
rs3181384 0.20 0.694 0 (167) 93.157 ± 1.598
(30UTR) (0.003) 1 (82) 90.917 ± 2.281
2 (12) 90.642 ± 5.962
Regression analysis was used to investigate the association between LTB4R
SNPs and baseline percent predicted FEV1 in the Adult Asthma Cohort (n=299)
using the additive model. 0, 1, 2 represent number of genotypes for major,
heterozygotes and minor genotypes respectively. *Dominant model analysis
was completed for rs2332320 due to low number of minor allele homozygotes
in the additive model.
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highest in severe asthmatics when compared to moderate
asthmatics and control subjects [24]. The LTB4-LTB4R
interaction is responsible for the influx of inflammatory
cells into the lung. A significantly reduced recruitment of
eosinophils and neutrophils into the airways has been
demonstrated in mice deficient in LTB4R compared
to wild type littermates [25]. Murine studies also
show LTB4 is responsible for CD8+ T-cell mediated
airway hyperresponsiveness through a mechanism in-
volving mast cells [26]. These studies suggest LTB4
contributes to asthma pathogenesis through the re-
cruitment and activation of neutrophils and eosino-
phils. Blocking the LTB4-LTB4R interaction with the
inhibitor LY293111 led to a reduction in BAL neutro-
phils [27] and with the inhibitor U75302 reduced the
migration and proliferation of airway smooth muscle
cells which contributes to airway remodelling [28].
These data suggested a potential role in both the in-
flammatory and structural changes observed in the
asthmatic airway.
Polymorphisms spanning ALOX5AP and LTA4H show
association with LTB4 production from ionmycinstimulated neutrophils [5,6]. We have previously
reported evidence that these same polymorphisms are
associated with asthma susceptibility [7]. To date, little
is known about the molecular structure of the two
receptors for LTB4 (LTB4R1 and LTB4R2) in lung and
peripheral cells/tissues and regarding the effect of poly-
morphism contributing to asthma and severity pheno-
types. Knowledge of the LTB4R1 and LTB4R2 isoforms
and their expression pattern in effector cells will be use-
ful when designing receptor antagonists and the effect of
polymorphic variation across the receptors may show
pharmacogenetic effects. We hypothesised that in
addition to genes involved with LTB4 synthesis, altera-
tions in genes encoding LTB4 target receptors may alter
cellular responses to LTB4, such as inflammatory cell in-
flux and contribute to asthma susceptibility and severity.
LTB4R1 shows varied structure at the mRNA level with
different 50-untranslated structures and transcription start
sites (TSS), whereas LTB4R2 is more conserved. For
LTB4R1, RACE identified a varied 50-untranslated struc-
ture with three 50-untranslated exons and one 30-
untranslated exon. This contrasted with previous findings
suggesting three exons in the monocytic cell line THP-1
[29]. Our findings and those from Kato et al. supported
the open reading frame (ORF) being contained in a single
exon which showed concordance with other GPCRs
showing intronless 50 exons [29,30]. The homogeneity of
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variants being authentic. Previous studies have suggested
LTB4R1 contains one 50-untranslated exon which is differ-
entially spliced [10].
These different 50-terminal exons give at least three
different regions for transcriptional control across the
LTB4R locus. Two different transcription start sites in
LTB4R1 at positions −4150 to −4148 and −748 to −758
and in LTB4R2 at position −5512 (relative to LTB4R1
ATG) were identified. -4150 has been reported in THP-1
cells and found to be active [29], supporting our finding
of this TSS in the lung. The sequence for these tran-
scription start sites were also identified in other lung
and peripheral cells based on our PCR screen. Further
characterisation of the promoter regions identified is
needed to determine whether they are cell-specific. Our
bioinformatic screen for transcription factor binding
sites has shown multiple Sp-1 and AP-1 motifs in the
promoter regions defined by TSS −5512 and −4150 to
−4148, but not in the −748 to −758 region. Sp-1 is re-
sponsible for basal transcription and AP-1 is involved in
inflammation, suggesting these promoter regions may be
utilised under these conditions. The promoter region
defined by −748 to −758 does not contain these motifs,
but contains a GR (glucocorticoid receptor) site. GRs are
transcription factors that are activated when bound to
steroids. Activated GR can interact with other transcrip-
tion factors, which can be positive (anti-inflammatory)
or negative. The latter is observed in patients with ster-
oid resistant asthma where transcription factors inacti-
vate GR; a study has shown AP-1 may interfere with the
binding of GR to DNA in steroid resistant patients [31].
Due to the close arrangement of LTB4R1 and LTB4R2
on chromosome 14q11.2 and the overlapping promoter
region of LTB4R1 being in the ORF of LTB4R2 [11]
raises the possibility that expression of these genes is
regulated by the use of different promoters and may
have cell-specific expression patterns. The complex 50-
untranslated region suggests transcriptional regulation
may be important for tissue-specific regulation of the
LTB4R1 gene. This complexity can also lead to
decreased efficiency of translation [32], which may be an
important consideration when developing antagonists to
target these receptors.
We screened the LTB4R locus to determine the level
of polymorphic variation across the receptors in the
Caucasian population. 22 SNPs were validated in our
UK population. Previously suggested non-synonymous
polymorphisms (which were identified in the Japanese
population) in LTB4R1 (rs34645221, Ala79Ser and
rs17849864, Leu346Phe) and LTB4R2 (rs1950504,
Asp196Gly) [33] were not validated. 14 validated SNPs
were at the 50-end of the LTB4R locus, in the predicted
LTB4R2 promoter location. Of these 4 novel SNPs wereidentified. These had a low MAF (<0.05) and to date
have not been reported in genetic databases or the
1000genomes browser. These could potentially affect
transcriptional efficiency (of either LTB4R2 or both
LTB4R1 and LTB4R2 due to the close location of these
genes). Our data also suggest strong linkage disequilib-
rium between the SNPs and a conserved nature of the
locus which gives support for the two genes being
formed by duplication during evolution [11].
Our studies did not observe any significant association
with asthma, FEV1 or severity (BTS defined) in the
asthma families or adult asthmatics for any LTB4R SNP
analysed. These analyses suggest that these traits may
not be genetically determined with respect to LTB4R
polymorphism. Although there was no significant associ-
ation, our data does show a constant direction of effect,
suggesting this study may be underpowered to detect a
subtle effect. Interestingly, there was modest evidence
for a role of ALOX5AP and LTA4H SNPs associated with
BTS defined asthma severity. These data therefore sug-
gest genetically determined leukotriene production may
be important in determining disease severity and not
alterations in the downstream LTB4R receptor expres-
sion/activity. While no other study has assessed the role
of LTB4R SNPs in asthma-related traits, research has
involved SNPs spanning these genes in the cardiovascu-
lar field, where leukotrienes have also been shown to
contribute to early atherosclerosis. rs1046587 and
rs3181384 (both LTB4R1, 30UTR) and three other SNPs
spanning LTB4R were tested for association with carotid
intima-media thickness in one study, but no association
was observed after correction for multiple testing [34].
Also no association was observed with rs1046587
(LTB4R1, 30UTR) and risk of ischemic stroke phenotypes
in UK and German stroke cohorts [21]. This study did,
however, identify significant or borderline association for
the four other LTB4R polymorphisms tested: rs2748543
and rs3181384 (both in strong LD) with cardioembolic
stroke in a UK cohort and rs1950505 and rs3742510
(also both in strong LD) with cardioembolic stroke in a
German cohort [21]. Only rs2748543 was shown to be
in LD with rs11158635 genotyped as part of this study.
Our study represents the first characterisation of the
LTB4R locus with respect to gene structure in the lung
and the first study to investigate association of LTB4R
SNPs with asthma and importantly asthma severity
where LTB4 has been suggested to have a more promin-
ent role. We acknowledge the limitations of this study.
One limitation was that RACE was conducted in the
lung tissue which hampered our ability to detect cell-
specific patterns of expression. Therefore it is likely that
novel transcripts which may occur in other cells of the
lung and periphery were not identified. To address some
of these issues we profiled the variants identified by
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show a ubiquitous expression profile in lung and periph-
eral cells and suggest that any antagonist targeting these
receptors is unlikely to be cell-specific. We acknowledge
that our sequencing cohort did not have the power to
detect very rare SNPs (0.1%), however we did search the
1000genomes project resource to see if any of our iden-
tified rare variant SNPs (those with MAF<0.05) were
validated by this project. Also there were modest num-
bers of families/individuals in our asthma cohorts used
for association analyses. For this reason replication in
larger additional cohorts is needed to validate our find-
ings. Similarly, our asthma subjects had relatively pre-
served lung function which may have impeded our
ability to detect association with FEV1 (% Predicted).
Conclusions
In conclusion, this study has shown that LTB4R1 and
LTB4R2 have complicated structure and are highly poly-
morphic. We also report the first evidence that SNPs
spanning these genes are not associated with asthma,
lung function or asthma severity.
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